Amneal Pharmaceuticals, Inc.
http://www.amneal.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amneal Pharmaceuticals, Inc.
Future Of GLP-1s: Iconovo Starts Development Of Intranasal Semaglutide
With asthma inhalers already in development, Iconovo has turned to a more innovative approach and looks at transforming injectable semaglutide into an intranasal drug.
US Generics Players Enjoy Calmer Waters
After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape.
Generics Bulletin Explains: US Generics Players Enjoy Calmer Waters
After years of heavy price and cost pressures that have taken a toll on firms operating in the US generics market, more recent quarters appear to have reflected a calmer and more predictable landscape. Generics Bulletin looks at the latest trends.
‘Inhalation Is A New Vector Of Growth’ For Amneal As Albuterol Goal Date Gets Closer
Amneal continues to grow its complex product portfolio, with multiple biosimilars and injectables launches coming in the near future, giving the firm confidence to raise its guidance.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Amedra Pharmaceuticals LLC
- Amneal Pharmaceuticals, LLC
- CorePharma LLC
- Gemini Laboratories, LLC
- Impax Generics
- Impax Laboratories, Inc. (IPXL)
- Impax Specialty Pharma
- Lineage Therapeutics Inc.
- Tower Holdings, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice